Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $670.0 million.

  • Relay Therapeutics' Liabilities and Shareholders Equity fell 2796.59% to $670.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year decrease of 940.32%. This contributed to the annual value of $871.3 million for FY2024, which is 323.66% up from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Liabilities and Shareholders Equity is $670.0 million, which was down 2796.59% from $728.8 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q3 2022 and a low of $670.0 million during Q3 2025
  • Its 5-year average for Liabilities and Shareholders Equity is $875.7 million, with a median of $871.3 million in 2024.
  • As far as peak fluctuations go, Relay Therapeutics' Liabilities and Shareholders Equity surged by 10526.7% in 2021, and later plummeted by 2796.59% in 2025.
  • Quarter analysis of 5 years shows Relay Therapeutics' Liabilities and Shareholders Equity stood at $1.0 billion in 2021, then rose by 9.06% to $1.1 billion in 2022, then dropped by 23.26% to $844.0 million in 2023, then increased by 3.24% to $871.3 million in 2024, then decreased by 23.1% to $670.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $670.0 million in Q3 2025, compared to $728.8 million in Q2 2025 and $799.4 million in Q1 2025.